�A unexampled study has shown that a
nasal hepatitis B vaccine elicits a dramatic immune response in animals
without requiring three vaccinations, sterile syringes or
refrigeration-three factors that impede the delivery of current hepatitis B
vaccines.
In the study, a single dosage of the nasal vaccine triggered a protective
reaction in animals roughly 450 times greater than that elicited by
currently sanctioned human vaccines. The brute studies establish a
magnitude of immunity that has not been seen in advanced preclinical
testing of other nasal vaccines, according to the scientists at the
University of Michigan and NanoBio Corp.
Moreover, the mucosal vaccine produced three distinct types of
immunity-mucosal, cellular and systemic-which enabled a rapid immune
response that could pop virus-infected cells and prevent future
infections. Traditional injected vaccines do not elicit mucosal or cellular
exemption.
The
